Irina Shapiro
Vice President - Translational Research Cullinan Therapeutics
Cancer biologist with 10+ years of translational research, oncology and immune oncology drug development experience. Strong expertise in mechanism of action studies, biomarker discovery and validation, characterization of anti-tumor immune responses using immunohistochemistry, multiplex immunofluorescence, genomic and proteomic analysis. Translational biomarker strategy development and implementation in immune oncology clinical trials (Phase I POC to Phase III/BLA submission).
Seminars
Advancing Clinical Biomarkers for Immune Reset to Definitively Characterize the B-Cell Repertoire & Success of Cell Therapies & T-Cell Engagers
Join this workshop to explore how immune resetting is being measured in the clinic:
- Assessment of B-cell reset in peripheral blood and tissue biopsies across autoimmune diseases
- Comparison of B-cell dynamics in lupus, rheumatoid arthritis, and Sjögren’s disease, including B-cell phenotyping and the impact of prior therapies
- CD19 T-cell engager development: expectations for detecting immune reset during dose escalation and the potential implications for Phase 2 dose and schedule selection
- B cell depletion and reconstitution following dual CD19/BCMA CART targeting in SLE/LN
- Phenotypes of B cells pre-treatment and post-reconstitution
- Potential comparison to other B cell targeting therapies
